Latest news with #StemCells
Zawya
10-03-2025
- Health
- Zawya
Abu Dhabi Stem Cells Center and Yas Clinic first in UAE to receive AABB accreditation for haematopoietic progenitor cell collection
Abu Dhabi: Abu Dhabi Stem Cells Center (ADSCC) and Yas Clinic have been granted a highly regarded global accreditation by AABB (formerly known as the American Association of Blood Banks) for Hematopoietic Progenitor Cell Collection. This achievement marks ADSCC and Yas Clinic as the first to earn this accreditation in the UAE, and the second in the Middle East and North Africa region (MENA), meeting the highest standards of quality and safety in in the procurement, processing, and storage of hematopoietic progenitor cells, which are critical for transplantation and treating various blood disorders and autoimmune diseases. As a Centre of Excellence in Hematopoietic Stem Cell Transplantation, accredited by the Department of Health Abu Dhabi and an accredited facility by the Foundation of Accreditation for Cellular Therapy (FACT), ADSCC and Yas Clinic's AABB accreditation further reinforces their commitment to excellence in cellular therapy and solidifies their leadership in regenerative medicine. Earning these three accreditations for cellular therapies in only 24 months is a testament to their dedication to the highest standards of quality, safety, and innovation in patient care within their Abu Dhabi Bone Marrow Transplant Program and their fully-fledged CAR-T and Mesenchymal Stem Cells programmes. Prof Yendry Ventura, Chief Executive Officer of ADSCC and Adjunct Professor at United Arab Emirates University, said: 'Under the visionary leadership of the UAE and in alignment with the national healthcare agenda, ADSCC and Yas Clinic remain dedicated to advancing cellular therapy and medical innovation on a global scale. Achieving AABB accreditation marks a significant milestone in our commitment to excellence in cellular therapies. As the first institution in the UAE to receive this prestigious accreditation, we continue to set new benchmarks in quality and patient safety which is backed by a solid infrastructure, a state-of-the-art apheresis and ECP unit, and unparalleled clinical expertise. This achievement underscores our dedication to pioneering cutting-edge treatments, enhancing healthcare standards, and reinforcing UAE's position as a regional leader in regenerative medicine and biological sciences.' Dr Maysoon Al Karam, Chief Medical Officer at Yas Clinic operated by ADSCC, said: 'This achievement reflects the efforts and expertise of our entire team of scientists, haematologists, immunologists, nurses and technicians and beyond. Being one of only two AABB-accredited facilities in the MENA region for HPC collection is a significant milestone for our patients and also physicians, and we are proud to contribute to the advancement of cellular therapy in the UAE and beyond. This accreditation positions ADSCC and Yas Clinic as a regional leader in bone marrow transplant and cellular therapy and reinforces our role in providing cutting-edge treatments to patients.' AABB's accreditation programme is the leader in ensuring the highest level of quality and safety for the blood and biotherapies field. AABB's accreditation programme promotes the highest standards of care for patients, donors, processes and products in all aspects of transfusion medicine, biotherapies and relationship testing. About Abu Dhabi Stem Cells Center (ADSCC) Abu Dhabi Stem Cells Center (ADSCC) is a renowned healthcare institution in Abu Dhabi, UAE, specialising in advanced stem cell therapy, research, and regenerative medicine. ADSCC is the incubator of the Abu Dhabi Bone Marrow Transplant (AD-BMT©) program, the first comprehensive programme to provide autologous and allogeneic hematopoietic stem cells transplant (HSCT) for adult and paediatric patients in the UAE since 2020. As a Center of Excellence in Hematopoietic Stem Cell Transplantation accredited by the Department of Health - Abu Dhabi, ADSCC's holistic service model includes advanced research, clinical trials, translational care, and manufacturing capabilities. ADSCC has one of the region's most advanced and sophisticated research labs and a robust multidisciplinary hospital. It is the only center in the UAE to encompass a cell processing laboratory, a state-of-the-art apheresis unit, a stem cell collection unit, a Good Manufacturing Practice (GMP) laboratory, and dedicated multi-specialty outpatient clinics and inpatient wards. As the UAE's first and most experienced stem cell transplant center, ADSCC has received multiple prestigious recognitions and conducted strategic collaborations, solidifying its position as a center of excellence. In 2024, ADSCC received accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT) for its cellular therapy processing laboratory, the first in UAE and one of only two in Middle East to receive this global accreditation.
Globe and Mail
24-02-2025
- Business
- Globe and Mail
Mesenchymal Stem Cells Market Share Projected 13.23 USD Billion, at a CAGR of 13% During 2025 to 2034
Mesenchymal Stem Cells Market Research Report 2025 By Products & Services (Workflow, Product and Services), By Type (Autologous and Allogenic), By Source of Isolation (Bone Marrow, Cord Blood, Peripheral Blood, Fallopian Tube, Fetal Liver, Lung and Adipose Tissues), By Indication (Bone and Cartilage Repair, Cardiovascular Disease, Inflammatory & Immunological Diseases, Liver Diseases, Cancer, GvHD and Others), By Application and Forecast 2034 Mesenchymal Stem Cells Market: A Regenerative Revolution The mesenchymal stem cells (MSCs) market is experiencing significant growth, driven by the therapeutic potential of these cells in regenerative medicine. MSCs, multipotent stromal cells that can differentiate into various cell types, hold promise for treating a wide range of diseases and injuries. As per MRFR analysis, the Mesenchymal Stem Cells Market Size was estimated at 3.90 (USD Billion) in 2024. The Mesenchymal Stem Cells Market Industry is expected to grow from 4.40 (USD Billion) in 2025 to 13.23 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 13.00% during the forecast period (2025 - 2034). The MSC market is characterized by intense research and development, with numerous clinical trials underway to evaluate the safety and efficacy of MSC-based therapies. The market is segmented by source (bone marrow, adipose tissue, umbilical cord blood, etc.), product type (cell lines, cell therapies), application (musculoskeletal disorders, cardiovascular diseases, autoimmune diseases, etc.), and region. Several key trends are shaping the MSC market: Rising Prevalence of Chronic Diseases: The increasing incidence of chronic diseases, such as osteoarthritis, diabetes, and cardiovascular disease, is driving demand for novel therapies, including MSC-based treatments. Advancements in Technology: Innovations in cell culture, differentiation, and delivery technologies are improving the efficacy and safety of MSC therapies. Growing Investment in R&D: Significant investments from both public and private sectors are fueling research and development in the MSC field. Key Companies in the Mesenchymal Stem Cells market include Lonza Group Thermo Fisher Scientific Inc. Merck KGaA StemCells Inc. Mesoblast Ltd. Cellular Dynamics International PromoCell GmbH Celgene Corporation Osiris Therapeutics, Inc. Pluristem Therapeutics Inc. In-Depth Market Analysis – Request Now: Mesenchymal Stem Cells (MSCs) Market Segmentation: By Products & Services: Workflow: Covers various stages involved in MSC research and therapy development, including cell isolation, expansion, characterization, and differentiation. Product: Encompasses MSC-based products, such as cell lines, cell therapies (both autologous and allogeneic), and related reagents and media. Services: Includes contract research organizations (CROs) offering MSC-related services, such as cell processing, analysis, and clinical trial support. By Type: Autologous: MSCs derived from the patient's own body, minimizing immune rejection risks. Allogeneic: MSCs derived from a donor, offering potential for off-the-shelf therapies. By Source of Isolation: Bone Marrow: A traditional source of MSCs, readily accessible and well-characterized. Cord Blood: A rich source of MSCs, often considered more primitive and having greater differentiation potential. Peripheral Blood: A less invasive source compared to bone marrow, gaining popularity for MSC isolation. Fallopian Tube: Emerging as a potential source with unique characteristics. Fetal Liver: A source with high proliferative capacity, though ethical considerations exist. Lung: A source with potential for lung-specific regenerative applications. Adipose Tissue: An abundant and easily accessible source, making it a popular choice for MSC isolation. By Indication: Bone and Cartilage Repair: MSCs are used to treat osteoarthritis, fractures, and other musculoskeletal conditions. Cardiovascular Disease: MSCs are explored for their potential to repair damaged heart tissue and improve cardiac function. Inflammatory & Immunological Diseases: MSCs' immunomodulatory properties are investigated for treating autoimmune diseases like rheumatoid arthritis and multiple sclerosis. Liver Diseases: MSCs are explored for their potential to regenerate damaged liver tissue. Cancer: MSCs are being studied for their potential role in cancer therapy, including drug delivery and tumor targeting. Graft-versus-Host Disease (GvHD): MSCs are used to treat GvHD, a complication following stem cell transplantation. Other Indications: Includes applications in various other diseases and conditions, such as neurological disorders, wound healing, and diabetes. By Application: Disease Modeling: MSCs are used to create in vitro models of diseases to study their mechanisms and develop new therapies. Drug Development & Discovery: MSCs are used in drug screening and development to identify potential therapeutic agents. Stem Cell Banking: The cryopreservation of MSCs for future use in regenerative medicine. Tissue Engineering: MSCs are used to create engineered tissues and organs for transplantation. Toxicology Studies: MSCs can be used to assess the toxicity of various compounds. Other Applications: Includes research and applications in various other fields, such as cosmetics and anti-aging. Upgrade Your Experience – Purchase Now: Regional Analysis The Mesenchymal Stem Cells (MSCs) market is segmented by products & services (workflow, product, services), type (autologous, allogeneic), source of isolation (bone marrow, cord blood, peripheral blood, fallopian tube, fetal liver, lung, adipose tissue), indication (bone & cartilage repair, cardiovascular disease, inflammatory & immunological diseases, liver diseases, cancer, GvHD, others), application (disease modeling, drug development & discovery, stem cell banking, tissue engineering, toxicology studies, others), and region (North America, Europe, Asia-Pacific, Rest of the World). Market Dynamics: Drivers: The increasing prevalence of chronic diseases, technological advancements, and growing awareness of regenerative medicine are driving market growth. Challenges: Challenges include the complexity of MSC manufacturing, regulatory hurdles, and the need for more robust clinical trial data. Opportunities: The expanding applications of MSCs, the development of novel therapies, and the growing demand for personalized medicine offer significant opportunities for market players. Industry Development: The MSC industry is witnessing significant developments, including: Collaborations and Partnerships: Companies are increasingly collaborating and partnering to accelerate the development and commercialization of MSC therapies. Clinical Trials: Numerous clinical trials are underway to evaluate the safety and efficacy of MSCs in various indications. Regulatory Approvals: Several MSC-based therapies have received regulatory approvals in various countries, paving the way for wider adoption. Manufacturing Scale-up: Companies are investing in manufacturing facilities to scale up the production of MSCs to meet growing demand. Other Related Report Insights: Media Contact Company Name: Market Research Future Contact Person: Media Relations Email: Send Email Country: United States Website:
